

Department of Planning and Budget 2013 Fiscal Impact Statement

1. Bill Number: SB 1285

House of Origin	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

2. Patron: Newman, Stephen D.

3. Committee: Passed Both Houses

4. Title: Interchangeable biosimilar biological products; permits pharmacists to dispense

5. Summary: The enrolled legislation permits pharmacists to dispense a biosimilar that has been licensed by the U.S. Food and Drug Administration as interchangeable with a prescribed biological product unless the prescriber indicates such substitution is not authorized or the patient insists on the dispensing of the prescribed biological product. The bill requires any pharmacist who dispenses an interchangeable biosimilar to inform the patient prior to dispensing the biosimilar and provide the patient with retail cost information for both the prescribed biological product and the interchangeable biosimilar. Whenever a pharmacist or his designee dispenses an interchangeable biosimilar in the place of a prescribed biological product, the pharmacist or his designee must provide the patient with retail cost information for both the prescribed biological product and the interchangeable biosimilar. The bill also requires, until July 1, 2015, the pharmacist to notify the prescriber when he substitutes an interchangeable biosimilar for a prescribed biological product.

6. Budget Amendment Necessary: No

7. No Fiscal Impact

8. Fiscal Implications: None

9. Specific Agency or Political Subdivisions Affected: None

10. Technical Amendment Necessary: No

11. Other Comments: This bill is a companion to HB 1422.

Date: 2/20/13

Document: G:\2013 Fiscal Year\2013 GA Session\EFIS\Enrolled FIS 13\SB1285er.docx